| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.087 | 0.2 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | GDC-0941 | FIMM | pan-cancer | AAC | 0.29 | 0.2 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.053 | 0.2 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.052 | 0.2 |
| mRNA | serdemetan:SCH-529074 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |